Apimeds Pharmaceuticals US, Inc (APUS) Earnings History
Annual and quarterly earnings data from 2021 to 2025
Loading earnings history...
APUS EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
APUS Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export APUS earnings history in CSV or JSON format
Free sign-in required to download data
Apimeds Pharmaceuticals US, Inc (APUS) Earnings Overview
As of May 8, 2026, Apimeds Pharmaceuticals US, Inc (APUS) reported trailing twelve-month net income of -$6.00B, reflecting +50.0% year-over-year growth. The company earned $-551.47 per diluted share over the past four quarters.
Looking at the long-term picture, APUS's historical earnings data spans multiple years. The company achieved its highest annual net income of -$668,666 in fiscal 2022.
Apimeds Pharmaceuticals US, Inc is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including HALO ($317M net income, 22.7% margin), ACRS (-$65M net income, -829.6% margin), SLRX (-$5M net income), APUS has comparable earnings metrics. Compare APUS vs HALO →
APUS Earnings vs Peers
Earnings metrics vs comparable public companies
APUS Historical Earnings Data (2021–2025)
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$6.00B | -431639.6% | -$12M | $-0.55 | - | - |
| 2024 | -$1M | -78.7% | -$1M | $-1.10 | - | - |
| 2023 | $-777,694 | -16.3% | $-747,436 | $-0.61 | - | - |
| 2022 | $-668,666 | +34.8% | $-639,529 | $-0.53 | - | - |
| 2021 | -$1M | - | -$1M | $-0.81 | - | - |
See APUS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs APUS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare APUS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAPUS — Frequently Asked Questions
Quick answers to the most common questions about buying APUS stock.
Is APUS growing earnings?
APUS EPS is $-551.47, with earnings growth accelerating to +50.0%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-6.0B.
What are APUS's profit margins?
Apimeds Pharmaceuticals US, Inc net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are APUS's earnings?
APUS earnings data spans 2021-2025. The accelerating earnings trend is +50.0% YoY. Historical data enables comparison across business cycles.